Nuvectis Pharma (NVCT) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Key scientific insights

• Previous SRC inhibitors caused systemic side effects due to lack of specificity, prompting the design of a more selective compound.

• NXP900 was rationally designed to inhibit both catalytic and scaffolding domains of SRC kinase, leading to more complete inhibition.

• Crystallography shows NXP900 induces a closed, inactive SRC conformation, unlike prior drugs that leave the kinase partially active.

• Phase I-A studies showed 90-95% SRC inhibition at doses of 150 mg and above, significantly higher than previous inhibitors.

• Safety profile in early trials is favorable, with no major immunosuppression or cardiovascular issues observed.

Clinical development and trial updates

• Phase I-B trial began 6-7 months ago, with preliminary data expected in late July or early August.

• Patient selection in Phase I-B is enriched for mutations like YES1, FAT1, and YAP1, aiming to increase response rates.

• Five monotherapy cohorts target various lung cancer subtypes and mutation-driven groups; two combination arms are underway.

• Combination studies with TAGRISSO (osimertinib) and lorlatinib are based on preclinical and third-party data showing reversal of drug resistance.

• Additional combinations, including with RAS pathway inhibitors, are being explored following promising academic interest.

Market opportunity and financials

• Addressable patient populations are in the tens of thousands, much larger than previous oncology drug launches.

• Approximately 25,000 patients annually become resistant to TAGRISSO, representing a major target for combination therapy.

• Cash position at end of Q1 was $25 million, with a quarterly burn rate of $4.5 million, providing 16-17 months of runway.

• Data readouts are planned every three months following the initial summer update.

• Standard next-generation sequencing panels are sufficient for patient identification; no need for a new companion diagnostic.